U.S. markets closed
  • S&P Futures

    3,756.25
    -9.25 (-0.25%)
     
  • Dow Futures

    30,816.00
    -62.00 (-0.20%)
     
  • Nasdaq Futures

    12,405.00
    -50.00 (-0.40%)
     
  • Russell 2000 Futures

    2,132.90
    -11.60 (-0.54%)
     
  • Crude Oil

    64.42
    +0.59 (+0.92%)
     
  • Gold

    1,691.40
    -9.30 (-0.55%)
     
  • Silver

    25.26
    -0.20 (-0.77%)
     
  • EUR/USD

    1.1967
    -0.0011 (-0.10%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • Vix

    28.57
    +1.90 (+7.12%)
     
  • GBP/USD

    1.3901
    +0.0007 (+0.05%)
     
  • USD/JPY

    107.9300
    -0.0460 (-0.04%)
     
  • BTC-USD

    47,239.57
    -4,009.11 (-7.82%)
     
  • CMC Crypto 200

    944.49
    -42.72 (-4.33%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,359.11
    -571.00 (-1.97%)
     

EOLS Stock: The Big News That Has Evolus Shares Skyrocketing Today

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
William White
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Evolus (NASDAQ:EOLS) stock was on the rise Friday following news that it’s no longer dealing with lawsuits from AbbVie (NYSE:ABBV) and Medytox.

colorful pills and vials sitting on a table
colorful pills and vials sitting on a table

Source: Bukhta Yurii / Shutterstock.com

The legal battle between the companies was over Evolus selling Jeuveau. This is a prescription drug that is injected into muscles to temporarily reduce severe lines around the eyes. The allegations claimed that Evolus misused trade secrets for Jeuveau.

The news today is that AbbVie and Medytox are dropping all claims made against Evolus in their lawsuits. However, that doesn’t come without some stipulations. That includes Evolus now having to send royalty and milestone payments to the two companies.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Other conditions of the dropped charges include Evolus issuing shares of EOLS stock to Medytox. To go along with this, AbbVie and Medytox are granting it the right to continue selling Jeuveau in the U.S. It can also sell Nuceiva, Jeuveau’s name outside the U.S., in other regions.

The end of these lawsuits means new life for EOLS stock. Previously, the lawsuits were going to ban it from selling Jeuveau in the U.S. for 21 months. That would have been detrimental to Evolus as it’s the company’s only product.

EOLS investors are reacting positively to the news with increased trading to shares. As of this writing, more than 33 million shares of the stock have traded hands. To put that in perspective, its daily average trading volume is roughly 844,000 shares.

EOLS stock closed out trading on Friday up 71.7%.

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.

More From InvestorPlace

The post EOLS Stock: The Big News That Has Evolus Shares Skyrocketing Today appeared first on InvestorPlace.